Mabwell has completed a dual primary listing on the Main Board of the Hong Kong Stock Exchange following its earlier listing on the Shanghai Stock Exchange STAR Market, marking an A-to-H listing transition and its inclusion in Southbound Stock Connect.

• Offering details: The company issued 47,130,200 H shares under stock code 02493.HK, raising approximately HK$1.189 billion in gross proceeds.
• Product pipeline: Mabwell has received approvals for four products, with its lead asset 9MW2821, a Nectin-4-targeting antibody-drug conjugate, currently in Phase III clinical trials.
• Use of proceeds: Funds will support multi-indication clinical trials of 9MW2821, pipeline R&D in oncology and age-related diseases, and product commercialisation.

This summary is based on a press release issued by Mabwell.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.